An observational study in COVID-19 Acute Respiratory Distress Syndrome, Viral Disease and Critical Illness, sponsored by Croatian Society for Organ Support. Completed at 1 site in Croatia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-13.
Sponsored by Croatian Society for Organ Support · Observational
The ongoing COVID-19 pandemic caused high hospitalization and mortality rates especially in critically ill patients. Unfortunately, there is no present study with a large number of patients that would offer us clear answers on the treatment of ICU COVID-19 patients with adsorption filters, extracorporeal methods and the hemoperfusion method. The purpose of this registry study is to investigate the effectiveness and safety of the extracorporeal blood purification and hemoperfusion/hemadsorption filters in treating of critically ill COVID-19 patients.
The COVID-19 pandemic has been associated with high mortality rate and high percentage of patients with with severe multi-organ dysfunction. Many therapies were investigated in this group of patients. The usage of extracorporeal blood purification, namely hemoperfusion/hemadsorption was introduced in everyday clinical practice even before COVID-19 pandemic in which became increasingly common. The efficacy of hemoperfusion/hemadsorption in removal of endotoxins and cytokines is still questioned by some physicians mostly due to the fact that some trials failed to demonstrate the effect of this therapy on long-term outcomes of critically ill patients. Unfortunately, there is no present study with a large number of patients that would offer us clear answers on the treatment of ICU COVID-19 patients with adsorption filters, extracorporeal methods and the hemoperfusion method. Several extracorporeal blood purification therapies have been proposed to attenuate systemic inflammation in COVID-19 patients but there is no study which analyzed more than one filter or patients without specific conditions. Due to these limitations the studies were not able to analyze the method itself. Therefore, the primary aim of this observational prospective, multi-centric, regional web-based registry is to define the results and outcome of treatment, possible advantages over patients who have not undergone targeted treatment and to set regional indications/inclusion criteria for the treatment of ICU COVID-19 patients with the method of hemoadsorption/hemoperfusion.
927 studies on the registry are indexed under Virus Diseases; 112 are open to participants now.
This study's enrollment of 1,050 is above the median of 311 across 278 observational studies indexed under Virus Diseases.
Browse Virus Diseases studies →Croatian Society for Organ Support is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All medical institutions from South-East European countries (Slovenia, Croatia, Bosnia, Montenegro, Serbia, Macedonia, Albania, Kosovo, Greece, Italy, Turkey, Bulgaria and Romania) that provide extracorporeal blood purification treatments to COVID-19 critically ill patients are eligible for participation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
ICU COVID-19 patients treated with hemoperfusion/hemadsorption
Device: Hemoperfusion
ICU COVID-19 patients not treated with hemoperfusion/hemadsorption
Commercial membranes for extracorporeal blood purification (hemoperfusion)
Define the inclusion criteria for hemoperfusion in ICU COVID-19 patients
Define the inclusion criteria for extracorporeal blood purification (hemoperfusion) with different filters/hemadsorbers in ICU COVID-19 patients
Time frame: 28 days
To assess the correlation between hemoperfusion and positive short-term outcome
Define as to assess the correlation between hemoperfusion and positive short-term outcome (i.e. an improvement in hemodynamic stability, inflammatory status and respiratory status).
Time frame: 24 hours after hemoperfusion initiation
To assess the correlation between hemoperfusion and positive short-term outcome
Define as to assess the correlation between hemoperfusion and positive short-term outcome (i.e. an improvement in hemodynamic stability, inflammatory status and respiratory status).
Time frame: 72 hours after finishing all the hemoperfusion procedures
To assess the correlation between hemoperfusion and positive long-term outcome
To assess the correlation between hemoperfusion and positive long-term outcome, defined as patient survival at ICU discharge.
Time frame: 28 days
To assess the correlation between different filters/hemadsorbers and positive short-term outcome
Define as to assess the correlation between different filters/hemadsorbers and positive short-term outcome (i.e. an improvement in hemodynamic stability, inflammatory status and respiratory status).
Time frame: 24 hours after hemoperfusion initiation
To assess the correlation between different filters/hemadsorbers and positive short-term outcome
Define as to assess the correlation between different filters/hemadsorbers and positive long-term outcome (i.e. an improvement in hemodynamic stability, inflammatory status and respiratory status).
Time frame: 72 hours after finishing all the hemoperfusion procedures
To assess the correlation between different filters/hemadsorbers and positive long-term outcome
To assess the correlation between different filters/hemadsorbers and positive long-term outcome, defined as patient survival at ICU discharge.
Time frame: 28 days
The effects of filters/hemadsorbents in combination with other extracorporeal organ support therapies (i.e. ECMO, CRRT) on positive short-term outcome
The effects of filters/hemadsorbents in combination with other extracorporeal organ support therapies (i.e. ECMO, CRRT) on positive short-term outcome (i.e. an improvement in hemodynamic stability, inflammatory status and respiratory status).
Time frame: 24 hours after initiation of the procedure with the combination of filters/hemadsorbers and extracorporeal organ support therapy
The effects of filters/hemadsorbents in combination with other extracorporeal organ support therapies (i.e. ECMO, CRRT) on positive short-term outcome
The effects of filters/hemadsorbents in combination with other extracorporeal organ support therapies (i.e. ECMO, CRRT) on positive short-term outcome (i.e. an improvement in hemodynamic stability, inflammatory status and respiratory status).
Time frame: 72 hours after finishing all the procedures with the combination of filters/hemadsorbers and extracorporeal organ support therapy
The effects of filters/hemadsorbents in combination with other extracorporeal organ support therapies (i.e. ECMO, CRRT) on positive long-term outcome
The effects of filters/hemadsorbents in combination with other extracorporeal organ support therapies (i.e. ECMO, CRRT) on positive long-term outcome (i.e. an improvement in hemodynamic stability, inflammatory status and respiratory status).
Time frame: 28 days
Plan to share: No
Ran from Jul 2022 to primary completion in Feb 2025, 30 months.
Of 120 non-industry observational studies under Virus Diseases, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 48. This study's 30 months is above that.
Counting every sponsor, half of 140 studies reached it within 21 months; a quarter within 10 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Croatian Society for Organ Support